title: Antiplatelet therapy before, during, and after extremity revascularization.
abstract: Peripheral arterial disease (PAD) is well recognized as a marker for systemic atherosclerosis. Platelets play an essential role in all stages of the disease, contributing to both thrombosis and the development of atherosclerosis. Medication regimens to optimize outcomes in both patients who are to undergo revascularization and those who will be managed without interventional therapy must address antiplatelet therapy. Given the common cardiovascular and cerebrovascular comorbidities in patients with PAD, antiplatelet therapy has the potential to decrease thromboembolic events in addition to improving patency after interventions. This clinical update reviews the current literature and recommendations for antiplatelet therapy in patients with PAD.
authors.affiliation: Division of Vascular Surgery, University of California, Los Angeles, Los Angeles, Calif. Electronic address: jkyang@mednet.ucla.edu.
authors.forename: Jane K
authors.initials: JK
authors.lastname: Yang
authors.affiliation: Division of Vascular Surgery, University of California, Los Angeles, Los Angeles, Calif.
authors.forename: Juan Carlos
authors.initials: JC
authors.lastname: Jimenez
authors.affiliation: Division of Vascular Surgery, University of California, Los Angeles, Los Angeles, Calif.
authors.forename: Sinan
authors.initials: S
authors.lastname: Jabori
mesh_terms: D006801:Humans; D019990:Perioperative Care / Q000379:methods*; D058729:Peripheral Arterial Disease / Q000188:drug therapy* / Q000601:surgery*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D014656:Vascular Surgical Procedures
chemical_list: D010975:Platelet Aggregation Inhibitors